|
Volumn 5, Issue 2, 2002, Pages 90-95
|
Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer
a a b c d e f g h i j |
Author keywords
Advanced gastric cancer; Paclitaxel; Phase II study
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DEXAMETHASONE;
DIPHENHYDRAMINE;
PACLITAXEL;
RANITIDINE;
ADULT;
ADVANCED CANCER;
AGED;
ALOPECIA;
ARTICLE;
BONE MARROW SUPPRESSION;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONFIDENCE INTERVAL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG HYPERSENSITIVITY;
DRUG INDUCED DISEASE;
DRUG INFUSION;
DRUG RESPONSE;
DRUG TOLERABILITY;
FEASIBILITY STUDY;
FEMALE;
HUMAN;
JAPAN;
LEUKOPENIA;
MALE;
NEUTROPENIA;
PERIPHERAL NEUROPATHY;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
STOMACH CANCER;
SURVIVAL TIME;
ADENOCARCINOMA;
CANCER STAGING;
DRUG ADMINISTRATION;
MIDDLE AGED;
STOMACH TUMOR;
SURVIVAL;
ADENOCARCINOMA;
ADULT;
AGED;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMAN;
MALE;
MIDDLE AGE;
NEOPLASM STAGING;
PACLITAXEL;
STOMACH NEOPLASMS;
SUPPORT, NON-U.S. GOV'T;
SURVIVAL ANALYSIS;
HUMANS;
MIDDLE AGED;
|
EID: 0035986020
PISSN: 14363291
EISSN: None
Source Type: Journal
DOI: 10.1007/s101200200015 Document Type: Article |
Times cited : (96)
|
References (24)
|